thalidomide

Thalidomide (Thalomid) is a synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.

Thalidomide-NH-C4-NH-Boc is a synthesized conjugate used in PROTAC technology, combining a Thalidomide-based cereblon ligand with a linker.

Thalidomide-4-OH (E3 ligase Ligand 2) (Cereblon ligand 2) is the Thalidomide-based Cereblon ligand used to recruit of CRBN protein. Thalidomide-4-OH (Cereblon ligand 2) is a linker to form PROTACs

Thalidomide-propargyl, a Thalidomide-derived Cereblon ligand, facilitates the recruitment of Cereblon. It can be attached to the protein ligand via a linker, producing IMiD-containing PROTACs.

Thalidomide-5-methyl is a Thalidomide-based cereblon (CRBN) ligand used for the recruitment of CRBN protein.

Thalidomide-O-amido-C3-NH2 TFA (Cereblon Ligand-Linker Conjugates 16 TFA) is a synthesized E3 ligase ligand-linker conjugate incorporating a Thalidomide-based cereblon ligand and a linker used in PROTAC technology.

Amino-PEG6-Thalidomide is a PEG-based linker for PROTACs that joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the [ubiquitin-proteasome system] within cells.

Thalidomide-O-amido-C4-NH2 (Cereblon Ligand-Linker Conjugates 6) is a synthesized compound combining a Thalidomide-based cereblon ligand with a linker, serving as an E3 ligase ligand-linker conjugate for the synthesis of PROTACs[1].

Thalidomide-O-amido-C8-NH2 (Cereblon Ligand-Linker Conjugates 2) is a synthesized E3 ligase ligand-linker conjugate containing a Thalidomide-based cereblon ligand and a linker, useful in the synthesis of PROTACs, as per reference [1].

Thalidomide-O-amido-C3-COOH is a synthesized conjugate of an E3 ligase ligand-linker compound that combines a cereblon ligand (derived from Thalidomide) with a linker commonly employed in PROTAC technology.

Thalidomide-O-amido-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 3) is an E3 ligase ligand-linker conjugate developed using a Thalidomide-based cereblon ligand and a 3-unit PEG linker, synthesized specifically for use in PROTAC technology.

Thalidomide-O-amido-PEG2-C2-NH2 TFA (E3 Ligase Ligand-Linker Conjugates 24 TFA) is a synthesized E3 ligase ligand-linker conjugate incorporating the Thalidomide-based cereblon ligand and a 2-unit PEG linker, utilized in PROTAC technology.

Thalidomide-NH-C10-COOH (compound 6b) is a synthetic E3 ligase ligand-linker conjugate, combining the Thalidomide-based von Hippel-Lindau (VHL) ligand with a linker commonly used in PROTAC technology. [1]

Thalidomide-NH-C4-NH2 TFA (compound 29c) is a conjugate composed of an E3 ligase ligand-linker that integrates a Thalidomide-based cereblon ligand and a linker moiety. This compound is used as a component in PROTAC BRD2/BRD4 degrader-1, a highly potent and selective degrader targeting BET proteins BRD4 and BRD2[1].

Thalidomide-NH-C6-NH2 TFA is a synthetic conjugate compound that integrates a cereblon ligand derived from Thalidomide with a linker used in PROTAC technology, serving as an E3 ligase ligand-linker conjugate[1].

Thalidomide-NH-C6-NH2 is a synthetic conjugate designed as an E3 ligase ligand-linker, comprising a Thalidomide-based cereblon ligand connected to a specific linker used in PROTAC technology[1].

Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, combines a Thalidomide-based cereblon ligand with a two-unit PEG linker for use in PROTAC technology[1].

Thalidomide-O-amido-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology[1].

Thalidomide-NH-PEG7 is a synthesized conjugate of an E3 ligase ligand and linker, intended for use in antibody-drug conjugates (ADCs). It can be attached to a protein ligand via a linker to form PROTAC iRucaparib-AP6, a highly selective degrader of PARP1[1].

Thalidomide-O-amido-C4-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, combines the cereblon ligand derived from Thalidomide with a linker and is commonly used in the synthesis of PROTACs[1].

Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride, incorporating an E3 ligase ligand and a linker, can be used as an immunomodulator for the treatment of cancer.

Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, incorporates a cereblon ligand derived from Thalidomide and a 3-unit PEG linker. This compound is specifically designed for use in PROTAC technology, which utilizes small molecules to induce protein degradation [1].

Thalidomide-O-amido-PEG4-azide is a polyethylene glycol (PEG) derivative used as a linker in the synthesis of Proteolysis Targeting Chimeras (PROTACs) [1].

Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate, incorporating the Thalidomide-based cereblon ligand and a linker.